[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"barretts-esophagus-without-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:barretts-esophagus-without-dysplasia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100521611","assessment-of-a-minimally-invasive-collection-device-for-molecular-analysis-of-esophageal-samples-100521611",false,"NCT06071845","Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples","Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples for the Non-endoscopic Detection of Barrett's Esophagus With and Without Dysplasia","SOS4C","Inclusion Criteria:\n\n* Subjects with known or suspected Barrett's esophagus (BE) (cases)\n\n  * Patients between the ages of 18-90.\n  * Patients with a BE segment ≥ 1cm in maximal extent endoscopically or suspected BE in medical record.\n  * Histology showing evidence of intestinal metaplasia with or without presence of dysplasia or suspected BE in medical record.\n  * Undergoing clinically indicated endoscopy.\n* Subjects without known history of BE (controls)\n\n  * Undergoing clinically indicated diagnostic endoscopy\n\nExclusion Criteria:\n\n* For subjects with or without known evidence of BE (on history or review of medical records)\n\n  * Pregnant or lactating females.\n  * Patients who are unable to consent.\n  * Patients with current history of uninvestigated dysphagia.\n  * History of eosinophilic esophagitis, achalasia.\n  * Patients on oral anticoagulation including Coumadin, Warfarin.\n  * Patients on antiplatelet agents including Clopidogrel, unless discontinued for three to five days prior to the Cytosponge procedure.\n  * Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for three to five days prior to the Cytosponge procedure.\n  * Patients with history of known esophageal or gastric varices or cirrhosis.\n  * Patients with history of surgical esophageal resection for esophageal carcinoma.\n  * Patients with congenital or acquired bleeding diatheses.\n  * Patients with a history of esophageal squamous dysplasia.\n  * Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment.\n  * Patient has received chemotherapy class drugs or radiation to treat mediastinal or esophageal cancer.","ALL","18 Years","90 Years",{"count":21,"type":22},450,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE\u002Fesophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard registered trademark Esophagus test (OGE) test uses esophageal cytology specimens collected with a minimally invasive, non-endoscopic, encapsulated sponge sampling device to identify BE\u002FEAC biomarkers that indicate whether a patient should undergo diagnostic endoscopy. The OGE test is a simple and cost effective screening method that may lower barriers to widespread adoption of BE screening in at risk patients, resulting in increased and earlier detection of BE\u002FEAC.",[28,29,30,31],"Barrett Esophagus","Barretts Esophagus With Dysplasia","Barrett's Esophagus Without Dysplasia","Esophageal Adenocarcinoma","RECRUITING","2026-05-29",{"date":35,"type":36},"2026-06-02","ACTUAL",{"date":38,"type":36},"2023-10-16",{"date":40,"type":22},"2027-06-01",{"name":42,"class":43},"Mayo Clinic","OTHER",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100496563","phase-2-oral-bevacizumab-800cw-and-cetuximab-800cw-administration-to-detect-early-esophageal-adenocarcinomas-100496563","NCT05745857","Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas","A Phase 2 Intervention Study: Detection of Early Esophageal Neoplastic Lesions by Quantified Fluorescence Molecular Endoscopy Using Oral and Topical Administration of Bevacizumab-800CW and Cetuximab-800CW","SLURP","Inclusion Criteria:\n\n* BE patients without dysplasia and with suspected\u002Fdiagnosed low-grade dysplasia (LGD), high-grade dysplasia (HGD) or superficial EAC and planned diagnostic and\u002For therapeutic endoscopy\n* Written informed consent is obtained\n\nExclusion Criteria:\n\n* Patients under the age of eighteen.\n* Submucosal and invasive EAC, also defined as EAC with tumor, node and metastasis (TNM)-classification other than T1.\n* Previous radiation therapy for esophageal cancer\n* Known immunoglobulin allergy\n* Previous chemotherapy, immunotherapy or related surgery\n* Prior bevacizumab or cetuximab treatment\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent\n* Pregnancy or breast feeding.",{"count":54,"type":22},25,[56],"PHASE2","Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.",[30,59,31],"Barrett Oesophagitis With Dysplasia",[61,62,63,64],"Fluorescence molecular endoscopy","Spectroscopy","Barrett's esophagus","Esophageal adenocarcinoma","2026-04-07",{"date":67,"type":36},"2026-04-13",{"date":69,"type":36},"2023-09-15",{"date":71,"type":22},"2026-12",{"name":73,"class":43},"University Medical Center Groningen",1]